Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council

Journal of Clinical Oncology

Volumn 19, Issue 6, 2001, Pages 1629-1640

  De Wit, R ^a   Roberts, J T ^a   Wilkinson, P M ^a   De Mulder, P H M ^a   Mead, G M ^a   Fossa S D ^a   Cook, P ^a   De Prijck, L ^a   Stenning, S ^a   Collette, L ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; TUMOR MARKER;

ADOLESCENT; ADULT; ARTICLE; BIOEQUIVALENCE; BLOOD TOXICITY; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FACTORIAL ANALYSIS; GERM CELL TUMOR; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

EID: 0035868896     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.6.1629     Document Type: Article

References (11)

1. Treatment of testicular cancer: A new and improved model
2. Companson of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies
3. International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers
4. Evaluation of optimal duration of chemotherapy in favourable-prognostic disseminated germ cell tumors: Bleomycin and either vinblastine or etoposide
5. Investigations and staging: General aspects and staging classification
6. How to establish equivalence when the data are censored: A randomized trial of treatments for B non-Hodgkin lymphoma
7. Patients'and doctors'perception of long-term morbidity in patients with testicular cancer stage I: A descriptive pilot study
8. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial
9. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group
10. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: The Indian University experience
11. Bleomycin in germ cell tumor therapy: Not all regimens are created equal